Good Luck All.
" the ongoing litigation with -STMICRO represents a long-run risk" said kumar " IBD
1) 17 patents, which will last till 2023 and 2031.
2) 40 patents pending
Earlier this week, Ashok Kumar of Maxim Group reiterated its rating of Buy for this company and changed its price target from $15.5 to $17.